Anti-Human EGFR Recombinant Antibody (Panitumumab) (CAT#: TAB-020)

Recombinant monoclonal antibody to Human EGFR. Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 EGFR G465R mutant reveals almost complete abrogation of panitumumab and cetuximab binding.

Figure 1 EGFR G465R mutant reveals almost complete abrogation of panitumumab and cetuximab binding.

EGFR mutation G465R abrogates binding of panitumumab and cetuximab at the protein level. Wile-type and mutant EGFR-Fc proteins were expressed and the binding of therapeutic antibodies to immobilized proteins was assessed by ELISA. Data are means from 3 experiments +/- SEM. * p<0.05, ** p<0.01, n.s. = not significant (student's T-test comparing binding of respective antibody to mutant versus wt EGFR-Fc).

Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., ... & Engel, E. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035.

Figure 2 EGFR G465R mutant reveals almost complete abrogation of panitumumab and cetuximab binding.

Figure 2 EGFR G465R mutant reveals almost complete abrogation of panitumumab and cetuximab binding.

Panitumumab and cetuximab binding is abrogated in CHO cells transfected with EGFR G465R . EGFR negative CHO cells were transfected with wild type EGFR or mutants thereof. Binding of panitumumab, cetuximab or a control polyclonal EGFR antibody was assessed by FACS analysis 48h after transfection. FSC = forward scatter.

Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., ... & Engel, E. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035.

Figure 3 EGFR G465R mutation induces cross-resistance to panitumumab and cetuximab in an EGF-dependent Ba/ F3 cellular model.

Figure 3 EGFR G465R mutation induces cross-resistance to panitumumab and cetuximab in an EGF-dependent Ba/ F3 cellular model.

A: EGFR signaling in EGF-dependent Ba/F3 model. Wt and S492R or G465R mutant EGFR-expressing Ba/F3 cells were cultured in the presence or absence of EGF and with addition of cetuximab, panitumumab, rituximab or erlotinib. After 2 hours, cells were harvested and EGFR/pEGFR expression analyzed by western blot analysis. B: Sensitivity of EGFR wt or EGFR G465R mutant- transfected Ba/F3 cells to treatment with EGFR-targeted antibodies. Ba/F3 cells were transformed to IL-3 independence with EGFR wt or mutant constructs and subsequently cultured in the presence or absence of EGF or with EGF in combination with panitumumab, cetuximab or control antibody rituximab. The number of viable cells was determined by trypan blue exclusion every 12 hours beginning 24 hours after seeding and plotted. Data are means from triplicate experiments +/-SEM.

Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., ... & Engel, E. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035.

Figure 4 In vitro EGFR targeting of panitumumab.

Figure 4 In vitro EGFR targeting of panitumumab.

Immunofluorescence staining of UM-SCC-22B tumor cells and tissues for EGFR using panitumumab as the primary antibody.

Liu, Z., Liu, Y., Jia, B., Zhao, H., Jin, X., Li, F., ... & Wang, F. (2010). Epidermal growth factor receptor–targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Molecular cancer therapeutics, 1535-7163.

Figure 5 In vitro EGFR targeting of panitumumab.

Figure 5 In vitro EGFR targeting of panitumumab.

In vitro inhibition of 125I-panitumumab binding to EGFR on UM-SCC-22B human head and neck cancer cells by DOTA-panitumumab and panitumumab. Points, mean (n = 3); bars, SD.

Liu, Z., Liu, Y., Jia, B., Zhao, H., Jin, X., Li, F., ... & Wang, F. (2010). Epidermal growth factor receptor–targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Molecular cancer therapeutics, 1535-7163.


Specifications

  • Immunogen
  • EGFR expressed on the surface of cells (A431 cells)
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG2 - kappa
  • Specificity
  • Tested positive against native human antigen
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF, ICC
  • Trade name
  • vectibix
  • CAS
  • 339177-26-3
  • Generic Name
  • Panitumumab
  • Biological Half-Life
  • 9.4 days (range: 4-11 days)
  • ATC Code
  • L01XC08
  • DrugBank
  • DB01269
  • UNII
  • 6A901E312A
  • ChEMBL
  • CHEMBL1201827
  • MW
  • 144,324.12 g/mol
  • Related Disease
  • Colorectal cancers

Product Property

  • Purity
  • >95.0%. Determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • 4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided.

Applications

  • Application Notes
  • The EGFR antibody has been reported in applications of ELISA, FC, WB, IF, Inhib.
    IF: UM-SCC-22B cell staining study was done as previously described with some modifications (17). Briefly, 70% to 85% confluent tumor cells grown in 35-mm MatTek glass-bottomed culture dishes were fixed using 4% paraformaldehyde for 10 minutes. After blocking with 10% FBS in PBS for 30 minutes, the cells were incubated with panitumumab (5 μg/mL) for 1 hour. The cells were then washed with PBS and stained with FITC-coupled mouse anti–human IgG (hIgG) for 30 minutes. After the final wash with PBS, the cells were visualized using a Leica TCS-NT confocal microscope (Wetzler).

Target

  • Alternative Names
  • Panitumumab;vectibix;339177-26-3;ABX-EGF;ABX-EGF;Vectibix;DB01269EGFR;epidermal growth factor receptor;epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) , ERBB;ERBB1;erythroblastic leukemia viral (v erb b) o

Related Resources

  • Related Diseases
  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Panitumumab"

Afuco™ Anti-EGFR ADCC Recombinant Antibody (Panitumumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human EGFR. Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).

See other products for "EGFR"

Chimeric Antibody

CAT Product Name Application Type
TAB-003 Anti-Human EGFR Recombinant Antibody (Cetuximab) IF, IP, Neut, FuncS, ELISA, FC, ICC IgG1 - kappa
TAB-0225CL-S(P) Human Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-0225CL-S(P)) Block, Inhib, FuncS, Apop, In vivo Human scFv
TAB-272MZ Human Anti-EGFR Recombinant Antibody (TAB-272MZ) FuncS Chimeric (mouse/human) IgG
TAB-302MZ Human Anti-EGFR Recombinant Antibody (TAB-302MZ) ELISA Chimeric (mouse/human) IgG1
TAB-308MZ Human Anti-EGFR Recombinant Antibody (TAB-308MZ) FuncS Chimeric antibody (mouse/human)

Fc Glycosylation

High-mannose Glycoform

CAT Product Name Application Type
Gly-055LC-1 Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) ELISA Chimeric antibody (mouse/human)

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-167LC Recombinant Anti-Human EGFR Antibody (Non-glycosylated) ELISA Human antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0183MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody
BRD-0668MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody

Neutralizing Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-165 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Matuzumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-464CQ Afuco™ Anti-EGFR ADCC Recombinant Antibody (Tomuzotuximab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-003 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Cetuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-040 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-119 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Necitumumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-020. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare